{
  "source": "PA-Notification-Rezurock.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1366-4\nProgram Prior Authorization/Notification\nMedication Rezurock® (belumosudil)\nP&T Approval Date 9/2021, 9/2022, 9/2023, 9/2024\nEffective Date 11/17/2024\n1. Background:\nRezurock is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years\nand older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two\nprior lines of systemic therapy.1\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Rezurock will be approved based upon both of the following criteria:\na. Diagnosis of chronic graft-versus-host disease (chronic GVHD)\n-AND-\nb. History of failure of at least two prior lines of systemic therapy [e.g., corticosteroids,\nmycophenolate, tacrolimus, etc.]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Rezurock will be approved based on the following criterion:\na. Documentation of positive clinical response to Rezurock therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Rezurock [Package Insert]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; April 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org . Accessed August 1, 2024.\nProgram Prior Authorization/Notification - Rezurock® ( belumosudil)\nChange Control\n9/2021 N",
    "NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org . Accessed August 1, 2024.\nProgram Prior Authorization/Notification - Rezurock® ( belumosudil)\nChange Control\n9/2021 New program\n9/2022 Annual review with no change to coverage criteria. Added state\nmandate footnote.\n9/2023 Annual review with no change to clinical criteria. Updated references.\n9/2024 Annual review. Removed age criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}